Combination of squamous cell carcinoma antigen immunocomplex and alpha-fetoprotein in mid- and long-term prediction of hepatocellular carcinoma among cirrhotic patients

doi:10.3748/wjg.v27.i48.8343

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 48

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3659)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

361

WORD

HTML

1862

Figures (1-3)

270

Tables (1-4)

275

Sum=2855

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

295

Download

509

Sum=804

Dec 28, 2021 (publication date) through Nov 3, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study

World J Gastroenterol. Dec 28, 2021; 27(48): 8343-8356
Published online Dec 28, 2021. doi: 10.3748/wjg.v27.i48.8343

Full Size Figure Download Figure

Figure 3 Estimating two- and five-year hepatocellular carcinoma disease-free survival by using Kaplan-Meier method according to the squamous cell carcinoma antigen immunocomplex, alpha-fetoprotein and combination of those both in validation cohort. A: Squamous cell carcinoma antigen immunocomplex (SCCA-IgM); low-risk: < 124 AU/mL, high-risk: > 124 AU/mL; B: Alpha-fetoprotein (AFP); low-risk: < 5 ng/mL, high-risk: > 5 ng/mL; C: Combination of SCCA-IgM and AFP. AFP: Alpha-fetoprotein; SCCA-IgM: Squamous cell carcinoma antigen immunocomplex.

Citation: Gil-Gómez A, Rojas Á, Liu CH, Gallego-Duran R, Muñoz-Hernandez R, Fassina G, Pontisso P, Ampuero J, Romero-Gómez M. Combination of squamous cell carcinoma antigen immunocomplex and alpha-fetoprotein in mid- and long-term prediction of hepatocellular carcinoma among cirrhotic patients. World J Gastroenterol 2021; 27(48): 8343-8356
URL: https://www.wjgnet.com/1007-9327/full/v27/i48/8343.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i48.8343